Summary
Relationships between plasma concentrations of acebutolol (Ac) and its N-acetyl metabolite (Am) and pharmacological effects were studied in patients with essential hypertension. In an acute study (N=7) 400 mg oral acebutolol produced similar peak plasma levels of Ac and Am but Am had a longer half life. Group mean pulse and blood pressure fell significantly, although the size of individual blood pressure fall varied five-fold. There was no significant change in plasma renin activity. Correlations were found between drug concentration and β-blockade, assessed as % reduction in exercise tachycardia, and between both of these and the fall in post exercise systolic blood pressure. Similar comparisons were made in a chronic optimum dose study (N=11) both pre-dose and three hours post-dose. Am concentration was consistently higher than Ac at both times. Blood pressure was lowered equally pre-and post-dose when compared to placebo and plasma renin activity (PRA) was reduced on active treatment. Correlations were again shown between drug concentrations and β-blockade but none were found with changes in blood pressure or PRA. Between subject differences in blood pressure response could not be fully explained in terms of the other measurements but it is unlikely that pharmacokinetic differences are the major source of this variability.
Similar content being viewed by others
References
Ablad, B., Borg, K. O., Johnsson, G., Regårdh, C. G., Solvell, L.: Combined pharmacokinetic and pharmacodynamic studies on alprenolol and 4-hydroxy-alprenolol in man. Life Sci.14, 693–704 (1974)
Anavekar, S. N., Louis, W. J., Morgan, T. O., Doyle, A. E., Johnson, C. I.: The relationship of plasma levels of pindolol in hypertensive patients to effects on blood pressure, plasma renin and plasma noradrenaline levels. Clin. Exp. Pharmacol. Physiol.2, 203–212 (1975)
Atkinson, A. J., Strong, J. M.: Effect of active drug metabolites on plasma level-response correlations. J. Pharmacokinet. Biopharm.5, 95–109 (1977)
Bühler, F. R., Laragh, J. H., Baer, L., Vaughan, E. D., Brunner, H. R.: Propranolol inhibition of renin secretion. New Engl. J. Med.287, 1209–1214 (1972)
Cleaveland, C. R., Shand, D. G.: Effect of route of administration on the relationship between β adrenergic blockade and plasma propranolol level. Clin. Pharmacol. Ther.13, 181–185 (1972)
Cohen, E. L., Grim, C. E., Conn, J. W., Blough, W. M., Guyer, R. B., Kem, D. C., Lucas, C. P.: Accurate and rapid measurement of plasma renin activity by radioimmunoassay J. Lab. Clin. Med.77, 1025–1038 (1971)
Collste, P., Haglund, K., Frisk-Holberg, M., Orme, M. L'E., Rawlins, M. D., Östman, J.: Pharmacokinetics and pharmacodynamics of Alprenolol in the treatment of hypertension. Europ. J. clin. Pharmacol.10, 89–95 (1976)
Esler, M., Zweifler, A., Randall, O., DeQuattro, V.: Pathophysiologic and pharmacokinetic determinants of the antihypertensive response to propranolol. Clin. Pharmacol. Ther.22, 299–308 (1978)
Fitzgerald, J. D.: Why another beta antagonist? Postgrad. Med. J.53, (3) 52–57) (1977)
Fournier, A., Hardin, J. M., Alexandre, J. M., Lombaert, M., Ronco, G., Bezoc, J. F., Desmet, G., Quichaud, J.: Antihypertensive effect of acebutolol: its relation to sympathetic nervous system responsiveness and to plasma renin and dopamine-β-hydroxylase activities. Clin. Sci. Mol. Med.51, 477s-480s (1976)
Gradman, A. H., Winkle, R. A., Fitzgerald, J. W., Mcffin, P. J., Stoner, J., Bell, P. A., Harrison, D. C.: Suppression of premature ventricular contractions by Acebutolol. Circulation55, 785–791 (1977)
Gulaid, A., James, I. M., Kaye, C. M., Lewellen, O. R. W., Roberts, E., Sankey, M., Smith, J., Templeton, R., Thomas, R. J.: Lack of correlation between acetylator status and the production of the acetyl metabolite of acebutolol in man. Br. J. Clin. Pharmacol.5, 261–262 (1978)
Hansson, L., Berglund, G., Andersson, O., Holm, M.: Controlled trial of Acebutolol in Hypertension. Europ. J. clin. Pharmacol.12, 89–92 (1977)
Leonetti, G., Mayer, G., Morganti, A., Terzoli, L., Zanchetti, A., Bianchetti, G., Disalle, E., Morselli, P. L., Chidsey, C. A.: Hypotensive and renin suppressing activites of propranolol in hypertensive patients. Clin. Sci. Mol. Med.48, 491–499 (1975)
Littler, W. A., West, M. J., Honour, A. J., Sleight, P.: The variability of arterial pressure. Am. Heart J.95, 180–186 (1978)
Martin, M. A., Phillips, C. A., Smith, A. J.: Acebutolol in Hypertension — A double blind trial against placebo. Br. J. Clin. Pharmacol.6, 351–356 (1978)
Meffin, P. J., Harapat, S. R., Yee, Y. G., Harrison, D. C.: High pressure liquid chromatographic analysis of drugs in biological fluids. Analysis of Acebutolol and its major metabolite. J. Chromatogr.138, 183–191 (1977)
Meffin, P. J., Winkle, R. A., Peters, F. A., Harrison, D. C.: Acebutolol disposition after intravenous administration. Clin. Pharmacol. Therap.22, 557–567 (1978)
Menard, J., Bertagna, X., N'Guyen, P. T., Degoulet, P., Corvol, P.: Rapid identification of patients with essential hypertension sensitive to acebutolol (A new cardioselective β blocker). Am. J. Med.60, 886–890 (1976)
Regårdh, C. G., Johnsson, G., Jordö, L., Solvell, L.: Comparative bioavailability and effect studies on metoprolol administered as ordinary and slow release tablets in single and multiple doses. Acta Pharmacol. et Toxicol.36 (Suppl.) 45–58 (1975)
Shand, D. G.: Pharmacokinetics of propranolol. A review. Post-grad. Med. J.52 (4) 22–25 (1976)
Silas, J. H., Lennard, M. S., Tucker, G. T., Smith, A. J., Malcolm, S. L., Marten, T. R.: Why hypertensive patients vary in their response to oral debrisoquine. Br. Med. J.1977/I, 422–425
Stokes, G. S., Weber, M. A., Thornell, I. R.: β blockers and plasma renin activity in hypertension. Br. Med. J.1974/I, 60–62
Winkle, R. A., Meffin, P. J., Ricks, W. B., Harrison, D. C.: Acebutolol metabolite plasma concentration during chronic oral therapy. Br. J. clin. Pharmacol.4, 519–522 (1977)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Martin, M.A., Phillips, F.C., Tucker, G.T. et al. Acebutolol in hypertension: Relationships between drug concentration and effects. Eur J Clin Pharmacol 14, 383–390 (1978). https://doi.org/10.1007/BF00716378
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00716378